Prognostic Impact of Circulating Tumor Cells Assessed with the CellSearch System™ and AdnaTest Breast™ in Metastatic Breast Cancer Patients: the DETECT Study

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2012 Aug 17

PMID 22894854

Citations 86

Authors

Volkmar Muller

Sabine Riethdorf

Brigitte Rack

Wolfgang Janni

Peter A Fasching

Erich Solomayer

Bahriye Aktas

Sabine Kasimir-Bauer

Klaus Pantel

Tanja Fehm

Affiliations

Soon will be listed here.

Abstract

Introduction: There is a multitude of assays for the detection of circulating tumor cells (CTCs) but a very limited number of studies comparing the clinical relevance of results obtained with different test methods. The DETECT trial for metastatic breast cancer patients was designed to directly compare the prognostic impact of two commercially available CTC assays that are prominent representatives of immunocytochemical and RT-PCR based technologies.

Methods: In total, 254 metastatic breast cancer patients were enrolled in this prospective multicenter trial. CTCs were assessed using both the AdnaTest Breast Cancer and the CellSearch system according to the manufacturers' instructions.

Results: With the CellSearch system, 116 of 221 (50%) evaluable patients were CTC-positive based on a cut-off level at 5 or more CTCs. The median overall survival (OS) was 18.1 months in CTC-positive patients. (95%-CI: 15.1-22.1 months) compared to 27 months in CTC-negative patients (23.5-30.7 months; p<0.001). This prognostic impact for OS was also significant in the subgroups of patients with triple negative, HER2-positive and hormone receptor-positive/HER2-negative primary tumors. The progression free survival (PFS) was not correlated with CTC status in our cohort receiving different types and lines of systemic treatment (p = 0.197). In multivariate analysis, the presence of CTCs was an independent predictor for OS (HR: 2.7, 95%-CI: 1.6-4.2). When the AdnaTest Breast was performed, 88 of 221 (40%) patients were CTC-positive. CTC-positivity assessed by the AdnaTest Breast had no association with PFS or OS.

Conclusions: The prognostic relevance of CTC detection in metastatic breast cancer patients depends on the test method. The present results indicate that the CellSearch system is superior to the AdnaTest Breast Cancer in predicting clinical outcome in advanced breast cancer.

Trial Registration: Current Controlled Trials Registry number ISRCTN59722891.

Citing Articles

Plasma treatment can efficiently increase the attachment of pancreatic circulatory tumor cells to the surface.

Mahdian S, Mahmoudi-Aznaveh A, Mousavi S, Larijani B, Azizi Z, Javar H Discov Oncol. 2025; 16(1):222.

PMID: 39982607 PMC: 11845332. DOI: 10.1007/s12672-025-01988-4.

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them.

Foffano L, Cucciniello L, Nicolo E, Migliaccio I, Noto C, Reduzzi C Breast. 2024; 79:103863.

PMID: 39718288 PMC: 11872392. DOI: 10.1016/j.breast.2024.103863.

Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).

Rusnakova D, Aziri R, Dubovan P, Jurik M, Mego M, Pindak D Oncol Lett. 2024; 29(1):10.

PMID: 39492933 PMC: 11526295. DOI: 10.3892/ol.2024.14756.

Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?.

Fabisiewicz A, Szostakowska-Rodzos M, Grzybowska E Int J Mol Sci. 2024; 25(19).

PMID: 39408942 PMC: 11476589. DOI: 10.3390/ijms251910612.

Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.

Tang M, Zhang Z, Wang P, Zhao F, Miao L, Wang Y Acta Pharm Sin B. 2024; 14(8):3457-3475.

PMID: 39220884 PMC: 11365446. DOI: 10.1016/j.apsb.2024.04.034.

References

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

Hayes D, Walker T, Singh B, Vitetta E, UHR J, Gross S . Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol. 2002; 21(5):1111-7. DOI: 10.3892/ijo.21.5.1111. View

Pantel K, Alix-Panabieres C, Riethdorf S . Cancer micrometastases. Nat Rev Clin Oncol. 2009; 6(6):339-51. DOI: 10.1038/nrclinonc.2009.44. View

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

Muller V, Alix-Panabieres C, Pantel K . Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer. 2010; 46(7):1189-97. DOI: 10.1016/j.ejca.2010.02.038. View

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

Alix-Panabieres C, Schwarzenbach H, Pantel K . Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2011; 63:199-215. DOI: 10.1146/annurev-med-062310-094219. View

Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer E, Wallwiener D . Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009; 11(4):R59. PMC: 2750121. DOI: 10.1186/bcr2349. View

Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S . HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004; 101(25):9393-8. PMC: 438987. DOI: 10.1073/pnas.0402993101. View

10.

Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S . Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009; 11(4):R46. PMC: 2750105. DOI: 10.1186/bcr2333. View

11.

Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Bocher O, Albert W . The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 2007; 27(3A):1337-41. View

12.

Hayes D, Ethier S, Lippman M . New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat. 2006; 100(2):237-8. DOI: 10.1007/s10549-006-9253-5. View

13.

Andreopoulou E, Yang L, Rangel K, Reuben J, Hsu L, Krishnamurthy S . Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer. 2011; 130(7):1590-7. DOI: 10.1002/ijc.26111. View

14.

Wicha M, Hayes D . Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011; 29(12):1508-11. DOI: 10.1200/JCO.2010.34.0026. View

15.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

16.

Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R . Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2008; 115(3):581-90. DOI: 10.1007/s10549-008-0143-x. View

17.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

18.

Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M . Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010; 16(9):2634-45. DOI: 10.1158/1078-0432.CCR-09-2042. View

19.

Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C . Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res. 2003; 9(7):2598-604. View

20.

Van der Auwera I, Peeters D, Benoy I, Elst H, Van Laere S, Prove A . Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2009; 102(2):276-84. PMC: 2816650. DOI: 10.1038/sj.bjc.6605472. View